Clinical Trials

Current Investigator-Initiated Clinical Trials

IRB# 17991: Biodistribution of 11C PIB PET in Alzheimer’s Disease, Frontotemporal Dementia, and Cognitively Normal Elderly – Hoffman – NCT00811122

IRB# 20112: Preliminary Evaluation of the Efficacy of [F-18] fluorothymidine (FLT) to Differentiate Radiation Necrosis from Tumor Recurrence and as a Marker of Proliferation in Patients with Primary Brain Tumors – Hoffman – NCT00707343

IRB# 31720: STAGES Trial: Study of Adiposity, Growth and Endocrine Stages-Mihalopoulos – NCT01460784

IRB# 5729: Retrospective analysis of clinical imaging and various testing used in the characterization of dementia – Hoffman

IRB# 44704: Assessment of Primary and Metastatic Brain Tumor Hypoxia with 18F-Fluoromisonidazole, [18F]fluoro-2-deoxy-D-glucose (FDG) and [15O]water (H215O) – Hoffman – NCT01246869

IRB# 52591: Retrospective analysis of patients with history of primary brain neoplasm evaluated with FDG-PET for the presence of recurrent tumor versus tumor necrosis – Hoffman

IRB# 55264: A Phase 1b/2 Study of Repeat rAdiation, Minocycline, and Bevacizumab in patients with recurrent gliOma (RAMBO) – Cohen – NCT01580969

IRB# 58734: Radiation Dose in Humans from Orally Administered Tc99m-Heparin – Gleich

IRB# 68059: Investigation of the Roles of Inflammation and Cancer in the Development of Dementia and Other Cognitive Deficits – Hoffman

IRB# 68770: A Phase 2 Randomized Study comparing Radium Ra 223 dichloride + Enzalutamide with Enzalutamide alone in Men with Metastatic Castration Refractory Prostate Cancer –Agarwal – NCT02199197

IRB# 69515: Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment (Chemobrain) – Hoffman – NCT02317783

IRB# 74088: Vessel Wall Inflammation Treatment Targets – McNally – NCT03068442

IRB# 76422: Cognitive training and practice effects-Duff – NCT02301546

IRB# 80314: Development of Quantitative Imaging Biomarkers for Evaluating Sarcoma Patients – Yap – NCT02579980

IRB# 94980: New MRI methods applied to heart failure with preserved ejection fraction (HFpEF) – Di Bella – NCT02608944

IRB# 100669: Role of Left Ventricular Assist Devices in Myocardial Regeneration – Drakos

IRB# 102312: A Phase 2 study of Radium-223 and Radiotherapy in Hormone-Naïve Men with Oligometastatic Prostate Cancer to bone-Tward – NCT03304418

IRB# 103657: An Exploratory Phase 1B Study to Assess the Effects of Merestinib on Bone Metastases in Subjects with Breast Cancer – Cohen – NCT03292536

IRB# 104704: [18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors – Hoffman – NCT03276676

IRB# 106377: Enriching clinical trials requiring amyloid positivity with practice effects – Duff – NCT03466736

IRB# 108907: Prevention of Alzheimer’s Disease in Women: Risks and Benefits of Hormone Therapy – Continuation of “The Kronos Early Estrogen Prevention Study (KEEPS)Allred – NCT03718494

IRB# 113970: [18F]Fluciclovine Companion Imaging Study to Radium-223 and Radiotherapy in Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone (RROPE) Study: IIT Fluciclovine Prostate – Hoffman – NCT03707184


Current Sponsored Clinical Trials

IRB# 61075/CALGB 80803: Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer-Lloyd - NCT01333033

IRB# 96885/AbbVie M15-566: A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimer’s Disease-Foster – NCT02880956

IRB# 100294/ECOG-ACRIN EAI141: Early Assessment of Treatment Response in AML using FLT PET/CT Imaging – Kovacsovics – NCT02392429

IRB# 105512/Juno Therapeutics 017004: An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004) – Stephens – NCT03331198

IRB# 113165/Kite KTE-C19-107 (ZUMA-7): A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7) – Lee – NCT03391466


Completed Investigator-Initiated and Sponsored Clinical Trials

IRB# 21946: A Multi-modality Imaging Assessment of Chemobrain-Approved – Hoffman – NCT00708045

IRB# 22418: FDG-PET/CT in the Evaluation of Persistent Febrile Neutropenia in Cancer Patients – Hoffman – NCT00707213

IRB# 26198: Development of an Integrated Molecular Biomarker of Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients using Imaging Assessments and Genomic Modeling – Hoffman – NCT00708448

IRB# 31335: Multi-Tracer PET Assessment of Primary Brain Tumors-Approved – Hoffman – NCT00813566

IRB# 36478/SWOG S0816: A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkins Lymphoma using Interim FDG-PET Imaging-Long Term Follow – Glenn – NCT00822120

IRB# 43306: Practice Effects and Amyloid Imaging using 18F-39-F-6-OH-BTA1 known as [18F-GE067] or [18F]Flutemetamol-PET, FDG-PET, and MRI – Duff – NCT01202994

IRB# 43948: Multi-Tracer PET Assessment of Response in Various Malignancies in Experimental and Recently Approved Therapeutic Agents – Hoffman – NCT01243333

IRB# 51497/RTOG 1174: A Phase III Trial Of Adjuvant Chemotherapy Following Chemoradiation As Primary Treatment For Locally Advanced Cervical Cancer Compared To Chemoradiation Alone – Poppe – NCT01414608

IRB# 58133: Quantitative Cardiac MRI Perfusion for longitudinal Studies – DiBella – NCT02608944

IRB# 62842/CALGB 51101: C51101 A Randomized Phase II Trial of Myeloablative versus Non-myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma – Cohen – NCT01511562

IRB# 83706: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease – Foster – NCT02484547

IRB# 84919: Implications for Management of PET Amyloid Classification Technology (IMPACT) – Foster – NCT02778971

IRB# 90351: IMPACT 2: Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia (IDEAS) trial – Foster – NCT02781220

IRB# 93497: TANGO Phase III, Multi-Center, Randomized, 48 Weeks, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy and Safety of CER-001 on Vessel Wall Area in Patients with Genetically Defined Familial Primary Hypoalphalipoproteinemia and Receiving Background Optimized Lipid Therapy –Allred – NCT02697136

Contact Us

Center for Quantitative Cancer Imaging Director
Jeffrey Yap, PhD
jeffrey.yap@hci.utah.edu
801-213-5650

Senior Advisor to the Director
John M. Hoffman, MD
john.hoffman@hci.utah.edu
801-587-4064

Governance

HCI Senior Director Oversight
David Gaffney, MD, PhD